1. Home
  2. NEOV vs BNR Comparison

NEOV vs BNR Comparison

Compare NEOV & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NeoVolta Inc.

NEOV

NeoVolta Inc.

HOLD

Current Price

$3.42

Market Cap

97.7M

Sector

Miscellaneous

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$9.59

Market Cap

94.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOV
BNR
Founded
2018
2014
Country
United States
China
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.7M
94.4M
IPO Year
2022
2019

Fundamental Metrics

Financial Performance
Metric
NEOV
BNR
Price
$3.42
$9.59
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
4.0K
Earning Date
05-14-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,426,835.00
N/A
Revenue This Year
$150.56
$111.65
Revenue Next Year
$5.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
218.59
N/A
52 Week Low
$1.36
$6.79
52 Week High
$7.13
$41.72

Technical Indicators

Market Signals
Indicator
NEOV
BNR
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NEOV
BNR

About NEOV NeoVolta Inc.

NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: